This is an old revision of this page, as edited by Innerstream (talk | contribs) at 00:21, 3 January 2025 (new page). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 00:21, 3 January 2025 by Innerstream (talk | contribs) (new page)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Identifiers | |
|---|---|
IUPAC name
| |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H24N2O4S2 |
| Molar mass | 432.55 g·mol |
| 3D model (JSmol) | |
SMILES
| |
Anaprazole is a pharmaceutical drug used for the treatment of duodenal ulcers. It is classified as a proton pump inhibitor (PPI). It was approved for use in China in 2023. It is formulated as its sodium salt, anaprazole sodium, in enteric-coated tablets.
References
- . doi:10.1002/cpdd.1405.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ "Anaprazole Sodium Enteric-coated Tablets Approved for Marketing by China NMPA". National Medical Products Administration. 2023-06-25.
| Drugs for peptic ulcer and GERD/GORD (A02B) | |
|---|---|
| H2 antagonists ("-tidine") | |
| Prostaglandins (E)/ analogues ("-prost-") | |
| Proton-pump inhibitors ("-prazole") | |
| Potassium-competitive acid blockers ("-prazan") | |
| Others | |
| Combinations | |
| |
 | This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |